LYPD3 Recombinant Monoclonal Antibody

^Promotion

Datasheet

Code	CSB-RA013263MA2HU
Size	$49.9
	Order now
Promotion
Image	The Binding Activity of Human LYPD3 with Anti-LYPD3 recombinant antibody Activity: Measured by its binding ability in a functional ELISA.Immobilized Human LYPD3(CSB-MP013263HU) at 2 μg/mL can bind Anti-LYPD3 recombinant antibody. The EC₅₀ is 2.375-2.905 ng/mL. The Binding Activity of Macaca fascicularit LYPD3 with Anti-LYPD3 recombinant antibody Activity: Measured by its binding ability in a functional ELISA.Immobilized Macaca fascicularis LYPD3（CSB-MP6357MOV1） at 2 μg/mL can bind Anti-LYPD3 recombinant antibody.The EC₅₀ is 0.8819-1.688 ng/mL. The Binding Activity of Mouse Lypd3 with Anti-LYPD3 recombinant antibody Activity: Measured by its binding ability in a functional ELISA.Immobilized Mouse Lypd3(CSB-MP849681MO1) at 2 μg/mL can bind Anti-LYPD3 recombinant antibody. The EC₅₀ is 1.995-2.345 ng/mL. The Binding Activity of Rat Lypd3 with Anti-LYPD3 recombinant antibody Activity: Measured by its binding ability in a functional ELISA.Immobilized Rat Lypd3(CSB-MP013263RA) at 2 μg/mL can bind Anti-LYPD3 recombinant antibody. The EC₅₀ is 3.515-3.992 ng/mL.
Have Questions?	Leave a Message or Start an on-line Chat

Product Details
Related Products
Customer Reviews and Q&A
Target Background

Product Details

Uniprot No.

O95274

Target Names

LYPD3

Alternative Names

2310061G07Rik antibody; C4.4A antibody; GPI-anchored metastasis-associated protein C4.4A homolog antibody; GPI-anchored metastasis-associated protein homolog antibody; Ly6/PLAUR domain-containing protein 3 antibody; Lypd3 antibody; LYPD3_HUMAN antibody; Matrigel-induced gene C4 protein antibody; MIG-C4 antibody; SHINC3 antibody

Species Reactivity

Human, Rat, Mouse, Macaca fascicularis

Immunogen

Recombinant Human LYPD3 protein

Immunogen Species

Homo sapiens (Human)

Conjugate

Non-conjugated

Clonality

Monoclonal

Isotype

hIgG1

Clone No.

11G8

Purification Method

Affinity-chromatography

Concentration

It differs from different batches. Please contact us to confirm it.

Buffer

Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, PH 7.4

Form

Liquid

Tested Applications

ELISA

Recommended Dilution

Application	Recommended Dilution
ELISA	1:5000-1:50000

Protocols

ELISA Protocol

Troubleshooting and FAQs

Antibody FAQs

Storage

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Lead Time

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

Description

LYPD3, also known as C4.4A, is a GPI-anchored protein belonging to the Ly6/PLAUR domain family that has garnered significant attention in cancer research due to its association with metastatic progression. This protein is frequently overexpressed in various carcinomas and has been implicated in tumor cell migration and invasion, making it a compelling target for both basic research and therapeutic development, as evidenced by its connection to the antibody therapeutic lupartumab.

This recombinant monoclonal antibody, clone 11G8, offers researchers the consistency and reliability that comes with sequence-defined production. Unlike traditional hybridoma-derived antibodies, recombinant technology ensures that every lot performs identically to the last, eliminating the variability that can compromise longitudinal studies or multi-site collaborations. The human IgG1 isotype format and affinity-chromatography purification further contribute to its defined performance characteristics.

Functional ELISA validation demonstrates robust binding activity across multiple species, providing genuine cross-species reactivity for comparative studies. The antibody shows excellent sensitivity with EC50 values in the low nanogram range across human, mouse, rat, and cynomolgus macaque LYPD3 proteins. Notably, binding to macaque LYPD3 shows particularly high affinity with an EC50 of approximately 0.88-1.69 ng/mL, while human, mouse, and rat orthologs demonstrate EC50 values ranging from approximately 2-4 ng/mL. For ELISA applications, dilutions between 1:5000 and 1:50000 are recommended.

For researchers investigating LYPD3's role in cancer metastasis, tumor progression, or evaluating it as a therapeutic target, this antibody provides a well-characterized tool with documented multi-species utility, supporting translational research workflows from rodent models through primate studies.

Usage

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

Customer Reviews and Q&A

■ Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function

Supports cell migration. May be involved in urothelial cell-matrix interactions. May be involved in tumor progression.

Gene References into Functions

While in the healthy liver hepatocytes are C4.4A negative, data show that C4.4A is strongly expressed in hepatocellular carcinoma (HCC) with upregulation at the invasive front and in lung metastasis, indicating that C4.4A apparently contributes to HCC progression. PMID: 29048672
Our results are consistent with previous data in mouse embryogenesis and wound healing. Based on these findings, we conclude that this human TES model provides an excellent surrogate for studies of C4.4A and Haldisin expressions in human stratified epithelia. PMID: 29075641
Expression and crystallographic studies of the D1D2 domains of C4.4A have been reported. PMID: 28777093
LYPD3 has a role in the maintenance of colorectal cancer stem-like cells. PMID: 28238780
Highly expressed C4.4A protein in HER2-positive human breast cancers indicate a good prognosis. PMID: 23918676
overexpression of C4.4A correlates with metastatic potential of gastric cancer and C4.4A could be a novel independent prognostic marker for predicting outcome. PMID: 24935570
expression of the Ly6/uPAR-domain proteins C4.4A and Haldisin in non-invasive and invasive skin lesions PMID: 25414274
Tenascin-C expression was significantly associated with C4.4A expression in clinical esophageal squamous carcinoma samples suggesting that there may be a functional role for the C4.4A to induceTenascin-C in vivo. PMID: 23708783
findings suggest that a tight association between C4.4A and tumor budding may, in part, be due to C4.4A promoting epithelial-mesenchymal transition at the invasive front of colorectal cancer PMID: 22404718
the first explanation for the C4.4A contribution to wound healing and metastasis. PMID: 22431918
data indicate that expression of the C4.4A protein at the invasive front acts as a novel prognostic marker in colorectal cancer, possibly through invasion-related mechanisms PMID: 20825414
hAG-2 and hAG-3, human homologues of genes involved in differentiation, are associated with oestrogen receptor-positive breast tumours and interact with metastasis gene C4.4a and dystroglycan PMID: 12592373
High tumour cell C4.4A expression is associated with shorter survival for non-small cell lung cancer patients. PMID: 17706320
Overexpression of C4.4A is associated with invasion and metastasis of esophageal squamous cell carcinoma PMID: 17849475
we consider C4.4A as a candidate diagnostic marker in colorectal cancer, which possibly can be detected in body fluids PMID: 17912244
cleavage of C4.4A by ADAM10 and ADAM17 contributes to tumor progression PMID: 18979631

Hide All

Subcellular Location

Cell membrane; Lipid-anchor, GPI-anchor.

Tissue Specificity

Expressed in placenta, skin and urothelium. Found in suprabasal keratinocytes of chronic wounds. Weak expression is found in esophagus and peripheral blood mononuclear cells. Found in the majority of primary and metastatic transitional cell carcinomas (TC

Database Links

HGNC: 24880

OMIM: 609484

KEGG: hsa:27076

STRING: 9606.ENSP00000244333

UniGene: Hs.631594

Promotions

Email: [email protected]
Distributors Worldwide

Service

Phage Display Service

Antibody Service

Protein Service

Gene Synthesis Service

Oligo Synthesis Service

LYPD3: An Emerging Star in Solid Tumor Therapy Antibody FAQs What Is an Antibody? How to Choose an Antibody for Scientific Research? The difference between primary antibody and secondary antibod The Meaning of Irregular Antibody Screening Tag Antibodies, Your Good Partner in Protein Research How to Choose the Loading Control Antibodies?

Related pathways

Target Therapy

Call us

301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)

[email protected]

Address

No. 269, Shendun 5th Road, Donghu Hi-Tech Development Area, Hubei Province, 430206, P.R.China

Join us with

Subscribe newsletter

Leave a message

Message

Product >> Product Name：
Product >> Code：
Name： *
Email： *
Company/Organization：
Phone：
Since emails may get flagged by spam filters occasionally, we recommend leaving your phone number as a precaution. Your information is safe with us.
Question/Comment： *
Your Region： *
I'd like to receive email newsletters from Cusabio

Yes

No
How do you know CUSABIO?

Email

Distributor

Search engine

Advertisement

Others
CAPTCHA verification：
Please enter the characters shown. Click the image to refresh if unclear.

Place an order now

I. Product details

Product name *

Code *

Size *

Quantity *

Message

II. Contact details

Name *

Email address *

Company/Organization

Phone

III. Ship To

Address *

City *

State/Province *

Zip/Post code *

Country *

Attn Name *

Phone# *

IV. Bill To Same as Shipping Address